25 completed, 9 recruiting, 7 terminated, 4 active not recruiting. 21 Phase 2, 17 Phase 1, 8 Not applicable, 5 Phase 3, 2 Phase 4.
Follow Acute Lymphoblastic Leukemia (ALL): new trials by email Literature Review of Acute Lymphoblastic Leukemia (ALL) trials Research Report on Acute Lymphoblastic Leukemia (ALL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| CAYA Cancer Prospective Cohort Study Cancer, Pediatric Cancer | Recruiting | Resonance, Inc. | 6000 | 2026-09-18 | 2026-09-29 | |
| ReSeT in ALL 2: A Randomized, Controlled Pilot Trial Testing an Optimized, Multi-component Mobile Health Intervention to Reduce Sedentary Time in Early Adolescents and Young Adults (eAYAs) With ALL During Maintenance Therapy ReSeT2 Intervention - Acute Lymphoblastic Leukemia (ALL), Sedentary Behavior / Physical Inactivity | Not applicable | Not yet recruiting | Children's Hospital Los Angeles | 50 | 2026-09-01 | 2026-08-03 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia Soterix tVNS device, Soterix tVNS device (sham programmed), Sleep Quality - Survivor of Childhood Cancer, Insomnia | Not applicable | Recruiting | St. Jude Children's Research Hospital | 40 | 2026-03-31 | 2026-08-14 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| CAYA Cancer Retrospective Cohort Study Retrospective Medical Record Review - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Recruiting | Resonance, Inc. | 18000 | 2025-06-04 | 2026-09-29 | |
| Reduce Sedentary Time in Acute Lymphoblastic Leukemia Sedentary time intervention - Acute Lymphoblastic Leukemia (ALL) | Not applicable | Completed | Children's Hospital Los Angeles | 20 | 2024-07-01 | 2026-07-07 |
| CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms FCTX-CL19-1 (Tarcidomgen Kimleucel) - Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) | Phase 1 | Unknown | FamiCordTx | 6 | 2023-05-24 | 2024-09-19 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Bio-CAR-T BS Study Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 45 | 2022-04-26 | 2026-04-30 | |
| Bright Ideas - CIN Feasibility Study Bright Ideas - CIN Training - Acute Lymphoblastic Leukemia (ALL) | Not applicable | Recruiting | The Hospital for Sick Children | 75 | 2022-03-01 | 2025-01-31 |
| Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL) | Completed | Novartis Pharmaceuticals | 602 | 2021-08-03 | 2024-04-30 | |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) KYMRIAH, YESCARTA - Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL) | Completed | Novartis Pharmaceuticals | 273 | 2020-12-09 | 2022-07-01 | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 38 | 2020-01-27 | 2024-12-20 |
| Animal Assisted Interactions With Animal Robot in the Intensive Care Unit (ICU) PARO therapy seal - Acute Lymphoblastic Leukemia (ALL), Critical Illness | Not applicable | Completed | University of Nebraska | 19 | 2019-07-01 | 2024-12-16 |
| Safety and Efficacy Evaluation of CD19-UCART CD19-UCART - Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) | Not applicable | Suspended | Bioray Laboratories | 20 | 2019-06-01 | 2023-07-24 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Cyclophosphamide, Fludarabine, Thiotepa - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 69 | 2019-01-31 | 2026-09-15 |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study non intervational - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Unknown | Cellect Biotechnology | 12 | 2018-06-10 | 2019-11-26 | |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Navitoclax, Chemotherapy, Venetoclax - Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma | Phase 1 | Completed | AbbVie | 69 | 2017-11-27 | 2021-10-14 |
Showing 20 of 56. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (56) · Leukemia, Myeloid, Acute (26) · Myelodysplastic Syndromes (18) · Lymphoma, Non-Hodgkin (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Hodgkin Disease (8) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Hematologic Neoplasms (6) · Leukemia (6) · Neoplasms (6) · Leukemia, Myelomonocytic, Juvenile (5) · Recurrence (4) · Anemia, Aplastic (3) · Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3)
Hematologic Diseases (56) · Hemic and Lymphatic Diseases (56) · Immune System Diseases (56) · Immunoproliferative Disorders (56) · Leukemia, Lymphoid (56) · Lymphatic Diseases (56) · Lymphoproliferative Disorders (56) · Neoplasms by Histologic Type (56) · Leukemia (50) · Neoplasms (50) · Leukemia, Myeloid (27) · Disease Attributes (25) · Pathologic Processes (25) · Pathological Conditions, Signs and Symptoms (25) · Bone Marrow Diseases (21)
Cyclophosphamide (9) · fludarabine (7) · Cytarabine (5) · Melphalan (5) · Thiotepa (5) · Vincristine (5) · fludarabine phosphate (5) · Methotrexate (4) · blinatumomab (4) · venetoclax (4) · Dexamethasone (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Mercaptopurine (3) · thymoglobulin (3)
St. Jude Children's Research Hospital (7) · Novartis Pharmaceuticals (4) · AbbVie (3) · Gamida Cell ltd (3) · Center for International Blood and Marrow Transplant Research (2) · Charite University, Berlin, Germany (2) · Children's Hospital Los Angeles (2) · Jazz Pharmaceuticals (2) · Memorial Sloan Kettering Cancer Center (2) · Resonance, Inc. (2) · Spectrum Pharmaceuticals, Inc (2) · Amgen (1) · Armaceutica, Inc. (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Bambino Gesù Hospital and Research Institute (1)
United States (39) · France (10) · Italy (8) · Netherlands (8) · United Kingdom (8) · Israel (7) · Canada (6) · Australia (5) · Austria (5) · Denmark (5) · Norway (5) · Poland (5) · Singapore (5) · Spain (5) · Czechia (4)
Brandon Triplett, MD (3) · Mitchell Horwitz, MD (3) · Arend von Stackelberg, MD (2) · Alan S Wayne, MD (1) · Allen Yeoh, MBBS (1) · Amy Hobeika, PhD (1) · Ann Jakubowski, MD (1) · Breanna Hetland, PhD (1) · Brittany Ivory, MD (1)
PMID 39368878, PMID 22198152, PMID 23169518, PMID 23907766, PMID 24030379, PMID 24911148, PMID 25734008, PMID 26320102, PMID 27507877, PMID 27966809, PMID 28736577, PMID 29463563, PMID 29595064, PMID 30044693, PMID 30239252, PMID 30500954, PMID 30523748, PMID 31010660, PMID 31092732, PMID 31098682, PMID 31151984, PMID 32959985, PMID 33743795, PMID 33811823, PMID 34088831, PMID 34157093, PMID 36215217, PMID 36335655, PMID 36358694, PMID 37120136, PMID 37276496, PMID 37341952, PMID 37703995, PMID 38091578, PMID 39792934, PMID 40062648, PMID 40266036, PMID 41379293, PMID 42234929
2014 (1), 2017 (1), 2018 (1), 2025 (1), R01HL114591 (1)